MedTrace Logo

Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction

NCT00952744 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2071

Last updated 2012-01-18

No results posted yet for this study

Summary

While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI. A combination of both markers for the diagnosis of AMI early after the event is therefore expected to be advantageous.

Conditions

  • Acute Coronary Syndromes

Sponsors & Collaborators

  • Brahms AG

    lead INDUSTRY

Principal Investigators

  • Alan S Maisel, MD · Veteran's Affairs Medical Center San Diego, University of California San Diego

  • W Frank Peacock, MD · The Cleveland Clinic

  • Christian Mueller, MD · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952744 on ClinicalTrials.gov